Visceral Adiposity, HIV, and HCV: Biologic Mediators of Hepatic Steatosis
内脏肥胖、HIV 和 HCV:肝脂肪变性的生物介质
基本信息
- 批准号:8292083
- 负责人:
- 金额:$ 61.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdipose tissueAreaBiopsyCaliforniaCentral obesityCessation of lifeCirrhosisClinicalCollectionCore BiopsyDataDevelopmentDiseaseEndotoxinsEnrollmentEtiologyFatty AcidsFatty LiverFatty acid glycerol estersFibrosisFundingFutureGenotypeGut associated lymphoid tissueHIVHIV InfectionsHealthHepaticHepatitis CHepatitis C virusHepatocyteHistologicHistologyIndividualInfectionInflammationInflammatoryInjuryInsulin ResistanceInterventionLeadLinkLipoatrophyLiverLiver diseasesMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMeasuresMediator of activation proteinMedical centerMetabolicMorbidity - disease rateNonesterified Fatty AcidsObesityOverweightParticipantPathogenesisPathway interactionsPatientsPeripheralPersonsPrevalenceRelative (related person)Research PersonnelRisk FactorsSamplingSan FranciscoSeveritiesSex CharacteristicsSiteStagingSteatohepatitisTechniquesTimeTissuesUnited StatesVeteransVirus DiseasesVisceraVisceralWomanadiponectinantiretroviral therapybasechronic liver diseasecohortcomparison groupcytokineinflammatory markerliver biopsymeetingsmenmicrobialmortalitypromoterpublic health relevancesubcutaneous
项目摘要
DESCRIPTION (provided by applicant): Liver disease is a leading cause of morbidity and mortality in HIV-infected persons. Hepatitis C virus (HCV) coinfection is implicated in many of these cases, but other causes of liver injury are common in HIV infection. Elucidation of the factors responsible for liver disease among HIV-infected patients, with or without concurrent HCV is important for researchers who seek to understand the pathogenesis of liver disease, and for clinicians who treat this large group of patients. Hepatic steatosis (or fatty liver) is common in HIV infection and is associated with accelerated fibrosis progression, which can lead to cirrhosis and death, particularly in those with HIV/HCV coinfection. However, relatively little is known about the etiology of steatosis in HIV infection. In HCV infection, genotype 3 appears to be directly associated with steatosis, but is uncommon in the US. By contrast, in those with genotype 1 HCV infection (which is highly prevalent in the US), obesity may be a more important cause than HCV infection. In the absence of HCV infection, obesity is a common cause of steatosis; however, visceral obesity (which is the accumulation of adipose tissue around the viscera) may be a more important risk factor than overall body mass for steatosis. Different studies suggest that the consequences of visceral obesity (increased inflammatory cytokines, decreased adiponectin, insulin resistance, increased circulating free fatty acids or microbial translocation of gut-derived endotoxins) may induce steatosis. These potential mediators could also explain the proposed link between HIV infection (independent of visceral obesity) and steatosis. HIV replication has been associated with elevations in inflammatory markers; HIV- associated peripheral lipoatrophy with decreased adiponectin levels. HIV infection has also been associated with depletion of gut-associated lymphoid tissue leading to a "leaky gut" and microbial translocation. Thus there is reason to believe that HIV infection will be an important risk factor for steatosis, independent of HCV and visceral adiposity. We propose the following hypotheses: (1.1) HIV infection (alone or in combination with HCV) will be associated with a greater severity of steatosis than in those with neither infection;(1.2) Increased visceral adiposity will be associated with severity of steatosis;(1.3) Peripheral lipoatrophy and gut-associated microbial translocation will be the dominant factors associated with steatosis in HIV-infected patients;(2.1) After controlling for HIV, HCV, and visceral adiposity, insulin resistance will remain strongly associated with the severity of steatosis;(2.2) Circulating free fatty acid levels will be a dominant predictor of steatosis due to the increased free fatty acid flux to the liver from increased visceral adiposity and the inability to store fatty acids in the setting of HIV-associated subcutaneous adipose tissue loss;(2.3) Decreased adiponectin levels (due to HIV-associated lipoatrophy and inflammation) will explain a significant proportion of the HIV effect on steatosis;(3.1) HIV/HCV-coinfected will have a greater prevalence and degree of histologic steatohepatitis and fibrosis than HCV-monoinfected patients, due to an increased severity of steatosis;(3.2) Increased inflammation, decreased adiponectin, increased free fatty acids, and insulin resistance will explain the greater prevalence and degree of histologic steatohepatitis and fibrosis in HIV/HCV-coinfected compared to HCV- monoinfected patients. The objective of the proposed study is to identify the dominant biologic mediators of steatosis, in order to focus future mechanistic and interventional studies on the key pathways associated with the pathogenesis of steatosis and its progression. To accomplish this, 300 men and 100 women with HIV and HCV monoinfection, HIV/HCV coinfection and neither infection will be studied. State-of-the-art non-invasive magnetic resonance spectroscopy (MRS) will measure steatosis. MRS studies a larger area than a random core biopsy of liver tissue, provides a continuous measure of liver fat, and allows for the study of patients with HIV monoinfection and neither infection; biopsy is not clinically indicated in those without chronic liver disease.
PUBLIC HEALTH RELEVANCE: Liver disease is a leading cause of morbidity and mortality in HIV-infected persons. Hepatic steatosis (or fatty liver) is a frequent cause of liver disease in the US and is a particular concern for HIV-infected persons. Steatosis is common in HIV infection and is associated with accelerated fibrosis progression, which can lead to cirrhosis and death, particularly in HIV/HCV-coinfected persons. HCV infection appears directly associated with steatosis, but the etiology of steatosis in HIV remains unclear. Obesity (in particular, visceral obesity) appears to be a key promoter of steatosis in the absence of viral infection. Studies show that about 50% of HIV-infected and 75% of HIV-uninfected persons in the US are overweight or obese. It is therefore critical to understand the relation of HIV, HCV, and visceral adiposity with steatosis, and to identify biologic mediators (microbial translocation, inflammation, adipokine and metabolic alterations) in the pathogenesis of steatosis, so that interventions targeted to the dominant factors can be developed and studied.
描述(由申请人提供):肝病是 HIV 感染者发病和死亡的主要原因。许多此类病例都与丙型肝炎病毒 (HCV) 合并感染有关,但 HIV 感染也常见其他导致肝损伤的原因。阐明 HIV 感染患者(无论是否并发 HCV)导致肝病的因素对于寻求了解肝病发病机制的研究人员以及治疗这一大群患者的临床医生来说非常重要。肝脂肪变性(或脂肪肝)在 HIV 感染中很常见,并且与加速纤维化进展相关,这可能导致肝硬化和死亡,特别是对于 HIV/HCV 合并感染的患者。然而,对于 HIV 感染中脂肪变性的病因学知之甚少。在 HCV 感染中,基因型 3 似乎与脂肪变性直接相关,但在美国并不常见。相比之下,对于基因 1 型 HCV 感染(在美国非常流行)的人来说,肥胖可能是比 HCV 感染更重要的原因。在没有HCV感染的情况下,肥胖是脂肪变性的常见原因;然而,内脏肥胖(即内脏周围脂肪组织的积累)可能是比总体体重更重要的脂肪变性风险因素。不同的研究表明,内脏肥胖的后果(炎症细胞因子增加、脂联素减少、胰岛素抵抗、循环游离脂肪酸增加或肠道源性内毒素的微生物易位)可能会诱发脂肪变性。这些潜在的介质还可以解释 HIV 感染(独立于内脏肥胖)和脂肪变性之间的拟议联系。 HIV 复制与炎症标志物升高有关; HIV相关的外周脂肪萎缩伴随脂联素水平降低。 HIV 感染还与肠道相关淋巴组织的耗竭有关,导致“肠漏”和微生物易位。因此,有理由相信,HIV 感染将是脂肪变性的一个重要危险因素,与 HCV 和内脏肥胖无关。我们提出以下假设:(1.1) HIV 感染(单独或与 HCV 联合)与没有感染的人相比,与脂肪变性的严重程度相关;(1.2) 内脏脂肪增多与脂肪变性的严重程度相关;( 1.3) 外周脂肪萎缩和肠道相关微生物易位将是 HIV 感染者脂肪变性的主导因素;(2.1) 在控制 HIV 后, HCV、内脏肥胖、胰岛素抵抗仍与脂肪变性的严重程度密切相关;(2.2) 循环游离脂肪酸水平将是脂肪变性的主要预测因子,因为内脏肥胖增加导致游离脂肪酸流向肝脏的增加,并且循环游离脂肪酸水平将成为脂肪变性的主要预测因子。在 HIV 相关的皮下脂肪组织损失的情况下无法储存脂肪酸;(2.3) 脂联素水平降低(由于 HIV 相关的(脂肪萎缩和炎症)将解释HIV对脂肪变性的很大一部分影响;(3.1)由于脂肪变性的严重程度增加,HIV/HCV合并感染的患者比HCV单一感染的患者具有更高的组织学脂肪性肝炎和纤维化患病率和程度; (3.2) 炎症增加、脂联素减少、游离脂肪酸增加和胰岛素抵抗将解释组织学脂肪性肝炎的患病率和程度更高与单独感染 HCV 的患者相比,HIV/HCV 合并感染的患者出现纤维化。本研究的目的是确定脂肪变性的主要生物介质,以便将未来的机制和介入研究重点放在与脂肪变性发病机制及其进展相关的关键途径上。为了实现这一目标,将对 300 名男性和 100 名女性 HIV 和 HCV 单一感染、HIV/HCV 双重感染以及两者均未感染进行研究。最先进的非侵入性磁共振波谱 (MRS) 将测量脂肪变性。 MRS 研究的区域比肝组织的随机核心活检更大,提供肝脏脂肪的连续测量,并允许研究 HIV 单一感染和两种感染的患者;对于没有慢性肝病的患者,没有临床指征进行活检。
公共卫生相关性:肝病是艾滋病毒感染者发病和死亡的主要原因。肝脏脂肪变性(或脂肪肝)是美国肝脏疾病的常见原因,并且是艾滋病毒感染者特别关注的问题。脂肪变性在 HIV 感染中很常见,并且与加速纤维化进展有关,这可能导致肝硬化和死亡,特别是在 HIV/HCV 合并感染者中。 HCV 感染似乎与脂肪变性直接相关,但 HIV 脂肪变性的病因仍不清楚。在没有病毒感染的情况下,肥胖(特别是内脏肥胖)似乎是脂肪变性的关键促进因素。研究表明,美国约 50% 的 HIV 感染者和 75% 的未感染者超重或肥胖。因此,了解 HIV、HCV 和内脏肥胖与脂肪变性的关系至关重要,并确定脂肪变性发病机制中的生物介质(微生物易位、炎症、脂肪因子和代谢改变),以便针对主导因素采取干预措施。得到开发和研究。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Phyllis C Tien其他文献
Risk factors for nasopharyngeal carriage of resistant Streptococcus pneumoniae and detection of a multiply resistant clone among children living in the Yukon-Kuskokwim Delta region of Alaska.
阿拉斯加育空-库斯科奎姆三角洲地区儿童鼻咽部携带耐药肺炎链球菌的危险因素以及多重耐药克隆的检测。
- DOI:
10.1097/00006454-199611000-00011 - 发表时间:
1996 - 期刊:
- 影响因子:0
- 作者:
X. T. Ussery;B. Gessner;Harvey B. Lipman;John Elliott;Marilyn J. Crain;Phyllis C Tien;Alan J. Parkinson;Michael Davidson;R. Facklam;R. Breiman - 通讯作者:
R. Breiman
Phyllis C Tien的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Phyllis C Tien', 18)}}的其他基金
Inter-CFAR Women and HIV Biennial Symposium
Inter-CFAR 妇女与艾滋病毒双年研讨会
- 批准号:
10762305 - 财政年份:2023
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV and the Menopausal Transition: Effects on Steatosis and Fibrosis Progression
HIV、HCV 和绝经过渡:对脂肪变性和纤维化进展的影响
- 批准号:
9913999 - 财政年份:2016
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
10646200 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
10433950 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
8700317 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
10220710 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
9091390 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
10083072 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
8605380 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
HIV, HCV, and gender effects on Liver, Bone, and Vascular Health
HIV、HCV 和性别对肝脏、骨骼和血管健康的影响
- 批准号:
8875588 - 财政年份:2013
- 资助金额:
$ 61.75万 - 项目类别:
相似国自然基金
YTHDC1调控棕色脂肪组织大小、发育和能量代谢的作用机制研究
- 批准号:32371198
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
糖尿病脂肪组织中SIRT3表达降低进而上调外泌体miR-146b-5p促进肾小管脂毒性的机制研究
- 批准号:82370731
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于ADPN-Cer轴的柑橘黄酮调控能量负平衡奶牛脂肪组织脂解的分子机制
- 批准号:32302767
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ANGPTLs基因及其蛋白表达水平调控内脏脂肪组织影响健康衰老表型的前瞻性队列研究
- 批准号:82373661
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
Acvrl1调控脂肪组织巨噬细胞M1/M2极化改善肥胖的机制研究
- 批准号:82300973
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Impact of Per/Polyfluoroalkyl pollutants on vascular disease mechanisms
全氟烷基/多氟烷基污染物对血管疾病机制的影响
- 批准号:
10751239 - 财政年份:2023
- 资助金额:
$ 61.75万 - 项目类别:
Leptin signaling in the carotid body: mechanisms and consequences
颈动脉体中的瘦素信号传导:机制和后果
- 批准号:
10782846 - 财政年份:2023
- 资助金额:
$ 61.75万 - 项目类别:
Identifying Proteomic Markers of Exercise Training in Heart Failure
识别心力衰竭运动训练的蛋白质组标记
- 批准号:
10663612 - 财政年份:2023
- 资助金额:
$ 61.75万 - 项目类别:
Image-based risk assessment to identify women at high-risk for breast cancer
基于图像的风险评估可识别乳腺癌高危女性
- 批准号:
10759110 - 财政年份:2023
- 资助金额:
$ 61.75万 - 项目类别: